Illumina, Inc. $ILMN Stock: New Mexico Educational Retirement Board Cuts Stake

New Mexico Educational Retirement Board decreased its stake in Illumina, Inc. (NASDAQ:ILMN) by 76.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,500 shares of the life sciences company’s stock after selling 24,800 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Illumina were worth $2,053,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ILMN. Baker Tilly Wealth Management LLC boosted its stake in shares of Illumina by 3.3% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after purchasing an additional 42 shares in the last quarter. Ashton Thomas Securities LLC lifted its holdings in Illumina by 3.3% during the 3rd quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock valued at $369,000 after purchasing an additional 43 shares during the last quarter. Elevation Wealth Partners LLC lifted its holdings in Illumina by 19.7% during the 3rd quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company’s stock valued at $80,000 after purchasing an additional 48 shares during the last quarter. Evergreen Capital Management LLC boosted its position in Illumina by 0.5% in the third quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company’s stock valued at $2,593,000 after buying an additional 50 shares in the last quarter. Finally, Pinnacle Associates Ltd. raised its stake in shares of Illumina by 2.2% in the third quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company’s stock valued at $686,000 after acquiring an additional 54 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In related news, Director Keith Meister sold 299,336 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the transaction, the director directly owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. This trade represents a 17.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 1,601,541 shares of company stock worth $354,755,291 over the last ninety days. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Down 0.9%

NASDAQ:ILMN opened at $212.93 on Thursday. The stock has a 50-day moving average price of $249.39 and a two-hundred day moving average price of $179.08. Illumina, Inc. has a 1 year low of $112.65 and a 1 year high of $309.35. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. The stock has a market cap of $32.20 billion, a price-to-earnings ratio of 36.65, a PEG ratio of 2.92 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current year.

Latest Illumina News

These are some of the ILMN news items that stood out recently:

• Positive Sentiment: Illumina reported third-quarter 2026 revenue of $1.129 billion and net income of $220 million, and raised its full-year revenue outlook to $4.64 billion–$4.66 billion. The company cited a strong contribution from clinical sequencing consumables, reinforcing demand in a key growth area. Article: How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company introduced an ultrasensitive duplex sequencing workflow for molecular residual disease research, extending its circulating tumor DNA offerings in oncology. It was also selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments may support future clinical sequencing adoption. Article: Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Positive Sentiment: Daiwa Securities raised its price target on Illumina to $228 from $196, signaling improved analyst expectations. Article: Daiwa Securities Adjusts Price Target on Illumina to $228 From $196

Wall Street Analyst Weigh In

Several research firms have weighed in on ILMN. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Leerink Partners raised their price target on shares of Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Royal Bank Of Canada raised their price target on shares of Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Evercore restated an “underperform” rating on shares of Illumina in a research report on Friday, October 30th. Finally, Citigroup upped their price objective on Illumina from $113.00 to $210.00 and gave the stock a “sell” rating in a report on Monday, November 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $244.24.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.